BVX.L

BiVictriX Therapeutics plc
BiVictriX Therapcts. - Result of Annual General Meeting
24th July 2024, 16:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7183X
BiVictriX Therapeutics PLC
24 July 2024
 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Result of Annual General Meeting

 

Alderley Park, 24 July 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next  generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces that at the Company's Annual General Meeting held today at 3:00 pm at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions were duly passed.

 

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 25th June 2024.

 

Details of proxy votes received prior to the meeting will be made available on the Company's website at https://bivictrix.com/investor-relations/. 

 

The proxy results were as follows:

 

RESOLUTION NUMBER

VOTES FOR

VOTES AGAINST

VOTES WITHELD

TOTAL VOTES

1

10,739,609

0

0

10,739,609

2

10,739,609

0

0

10,739,609

2

10,057,109

682,500

0

10,739,609

4

10,057,109

682,500

0

10,739,609

5

10,064,609

675,000

0

10,739,609

6

10,064,609

675,000

0

10,739,609

 

ENDS

 

For more information, please contact:

 

BiVictriX Therapeutics plc


 

Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman

 

 

 

Email: info@bivictrix.com

 



 

SP Angel Corporate Finance LLP (NOMAD and Broker)

  Tel: +44 (0) 20 3470 0470


David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)



 

Panmure Liberum Limited (Joint Broker)

 

  Tel: +44 (0) 20 7886 2500


Rupert Dearden/Freddy Crossley/Emma Earl

 

ICR Consilium


 

Mary-Jane Elliott, Namrata Taak,

Max Bennett, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com

 



 


 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKQBPPBKDFOB]]>
TwitterFacebookLinkedIn